ASCO 2017 Coverage

Wait Times From Cancer Diagnosis to First Treatment Longer, Negative Impact on Survival

Wait Times From Cancer Diagnosis to First Treatment Longer, Negative Impact on Survival

Data from the National Cancer Database are indicating that wait times from cancer diagnosis to initial treatment were substantially longer over a 5-year period.

Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer

Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer

Adding a second HER2-blocker to standard care therapy after surgery for HER2-positive breast cancer may be modestly beneficial for some women.

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.

Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men

Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men

A survey of men with prostate cancer revealed that treatment-related factors impact treatment decisions differently in black men compared with white men.

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein demonstrated promising results.

Innovative Navigation Strategies: The Patient Care Connect Program

Innovative Navigation Strategies: The Patient Care Connect Program

Older cancer survivors typically have higher severity of disease and pre-existing conditions, which makes their cancer treatment additionally challenging. The Patient Care Connect Program was created to help address these issues.

Older Patients Under-Represented in Cancer Drug Clinical Trials

Older Patients Under-Represented in Cancer Drug Clinical Trials

Older adults are underrepresented in clinical trials of cancer drugs, according to study findings presented at the 2017 ASCO Annual Meeting.

Self-Reports on Adverse Effects From Younger Patients Are Reliable, Accurate

Self-Reports on Adverse Effects From Younger Patients Are Reliable, Accurate

Children and adolescent patients with cancer are able to accurately report subjective adverse events (AEs) they experience during their cancer treatment, and they are willing to do so.

Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients

Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients

The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs